Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies

被引:0
|
作者
M. Borrell-Pagès
D. Zala
S. Humbert
F. Saudou
机构
[1] Institut Curie,CNRS UMR 146
[2] Universitat Autonoma de Barcelona,Neurovascular Research Laboratory, Vall d’Hebron Hospital
关键词
CAG expansion; polyglutamine; aggregation; intracellular transport; transcription; signal transduction; therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Huntington’s disease (HD) is a neurodegenerative disorder that usually starts in middle age and is characterized by involuntary movements (chorea), personality changes and dementia, leading to death within 10–20 years. The defective gene in HD contains a trinucleotide CAG repeat expansion within its coding region that expresses a polyglutamine repeat in the protein huntingtin. Together with the characteristic formation of aggregates in HD, aberrant protein interactions and several post-translational modifications affect huntingtin during disease progression and lead to the dysfunction and death of selective neurons in the brains of patients. The exact molecular mechanisms by which mutant huntingtin induces cell death are not completely understood but may involve the gain of new toxic functions and the loss of the beneficial properties of huntingtin. This review focuses on the cellular functions in which huntingtin is involved and how a better understanding of pathogenic pathways can lead to new therapeutic approaches.
引用
收藏
页码:2642 / 2660
页数:18
相关论文
共 50 条
  • [31] Nucleocytoplasmic transport of huntingtin and Huntington's disease
    Truant, R
    CLINICAL NEUROSCIENCE RESEARCH, 2003, 3 (03) : 157 - 164
  • [32] Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis
    Andre, Ralph
    Carty, Lucy
    Tabrizi, Sarah J.
    CURRENT OPINION IN PHARMACOLOGY, 2016, 26 : 33 - 38
  • [33] Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy
    Jurcau, Anamaria
    Jurcau, Maria Carolina
    BIOMEDICINES, 2022, 10 (08)
  • [34] Mutant Huntingtin-Calmodulin Interaction: Potential Therapeutic Target for Huntington's Disease
    Kapadia, Khushboo
    Roy, Anuradha
    McDonald, Peter
    Klus, Nicholas
    Frankowski, Kevin
    Aube, Jeffrey
    Muma, Nancy
    FASEB JOURNAL, 2019, 33
  • [35] Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin - A potential mechanism for loss of huntingtin function in Huntington's disease
    Busch, A
    Engemann, S
    Lurz, R
    Okazawa, H
    Lehrach, H
    Wanker, EE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) : 41452 - 41461
  • [36] Therapeutic strategies for Huntington's
    Imbert, M.
    Griffith, G.
    Benchaouir, R.
    Beley, C.
    Dugovic, B.
    Leumann, C.
    Garcia, L.
    Goyenvalle, A.
    HUMAN GENE THERAPY, 2015, 26 (10) : A80 - A81
  • [37] Mitochondrial Dysfunction in Huntington's Disease: Pathogenesis and Therapeutic Opportunities
    Sharma, Aditi
    Behl, Tapan
    Sharma, Lalit
    Aelya, Lotfi
    Bungau, Simona
    CURRENT DRUG TARGETS, 2021, 22 (14) : 1637 - 1667
  • [38] Endothelial Dysfunction in Huntington's Disease: Pathophysiology and Therapeutic Implications
    Hu, Ning
    Chen, Zihao
    Zhao, Xinyue
    Peng, Xin
    Wu, Yimeng
    Yang, Kai
    Sun, Taolei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (04)
  • [39] Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments
    Roze, Emmanuel
    Saudou, Frederic
    Caboche, Jocelyne
    CURRENT OPINION IN NEUROLOGY, 2008, 21 (04) : 497 - 503
  • [40] Huntington\'s disease: Biology, therapeutic strategies, and translational challenges
    Munoz-Sanjuan, Ignacio
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242